Contents

Highlights of This Issue 2119

SPECIAL FEATURES

CCR Translations

2121 Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes! Hariharan Easwaran and Stephen B. Baylin See article p. 2360

2124 Double Down for a Double Win Pearl S. Huang See article p. 2316

2127 Competing Risk Analyses: How Are They Different and Why Should You Care? Rick Chappell See article p. 2301

2130 Choosing Phase II Endpoints and Designs: Evaluating the Possibilities Michael LeBlanc and Catherine Tangen See article p. 2309

Molecular Pathways

2133 Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications Robert J. Biggar

2138 Molecular Pathways: Pathogenesis and Clinical Implications of Microbiome Alteration in Esophagitis and Barrett Esophagus Liying Yang, Fritz Francois, and Zhiheng Pei

Review

2145 Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment Asher A. Chanan-Khan, Jesús F. San Miguel, Sundar Jagannath, Heinz Ludwig, and Meletios A. Dimopoulos

HUMAN CANCER BIOLOGY

2164 Expression of Epstein-Barr Virus–Encoded Proteins in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKL Naoko Kanemitsu, Yasushi Isobe, Azuchi Masuda, Shuji Momose, Morihiro Higashi, Jun-ichi Tamaru, Koichi Sugimoto, and Norio Komatsu


CANCER THERAPY: PRECLINICAL


<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2220</td>
<td>First Evidence That γ-Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF-κB Pathway</td>
</tr>
<tr>
<td>2230</td>
<td>The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin</td>
</tr>
<tr>
<td>2240</td>
<td>Improved Efficacy of Dendritic Cell–Based Immunotherapy by Cutaneous Laser Illumination</td>
</tr>
<tr>
<td>2250</td>
<td>Cytokine BAFF Gene Variation Is Associated with Survival of Patients with T-cell Lymphomas</td>
</tr>
<tr>
<td>2257</td>
<td>Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review</td>
</tr>
<tr>
<td>2269</td>
<td>cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes</td>
</tr>
<tr>
<td>2278</td>
<td>Tumor Epidermal Growth Factor Receptor and EGFR PT1606 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma</td>
</tr>
<tr>
<td>2290</td>
<td>Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2250</td>
<td>Cytokine BAFF Gene Variation Is Associated with Survival of Patients with T-cell Lymphomas</td>
</tr>
<tr>
<td>2257</td>
<td>Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2301</td>
<td>The Use and Interpretation of Competing Risks Regression Models</td>
</tr>
<tr>
<td>2309</td>
<td>Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints</td>
</tr>
<tr>
<td>2316</td>
<td>The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer</td>
</tr>
</tbody>
</table>

**BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency**

David S. Hong, Luis Vence, Gerald Falchook, Laszlo G. Radvanyi, Chengwen Liu, Vicki Goodman, Jeffery J. Legos, Sam Blackman, Antonio Sarmadillo, Razelle Kurzrock, Gregory Lizée, and Patrick Hwu
### A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck


### A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Eva Szabo, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg, and Giuseppe Giaccone

### Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study

Jonathan Shamash, Jimmy Jacob, Samir Agrawal, Thomas Powles, Katherine Mutsvangwa, Peter Wilson, and Justin Stebbing

### DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer

Kim Walter, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, Nithya Kartha, Leonardo Iniguez, Robert Soriano, Ling Hwu, Howard Stern, Zora Modrusan, Somasekar Seshagiri, Garret M. Hampton, Lukas C. Amler, Richard Bourgon, Robert L. Yauch, and David S. Shames

See commentary p. 2121

### Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth

Wilfred D. Stein, Julia Wilkerson, Sindy T. Kim, Xin Huang, Robert J. Motzer, Antonio Tito Fojo, and Susan E. Bates

### Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment

David N. Finegold, Catherine J. Baty, Kelly Z. Knickelbein, Shelley Perschke, Sarah E. Noon, Diana Campbell, Jenny M. Karlsson, Diana Huang, Mark A. Kimak, Elizabeth C. Lawrence, Eleanor Feingold, Stephen D. Meriney, Adam M. Brujsky, and Robert E. Ferrell

### Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Elizabeth A. Punnoose, Siminder Atwal, Weiquan Liu, Rajiv Baja, Bernard M. Fine, Brett G.M. Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkal, and Mark R. Lackner

### Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial


### DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer

Kim Walter, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, Nithya Kartha, Leonardo Iniguez, Robert Soriano, Ling Hwu, Howard Stern, Zora Modrusan, Somasekar Seshagiri, Garret M. Hampton, Lukas C. Amler, Richard Bourgon, Robert L. Yauch, and David S. Shames

See commentary p. 2121

### Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth

Wilfred D. Stein, Julia Wilkerson, Sindy T. Kim, Xin Huang, Robert J. Motzer, Antonio Tito Fojo, and Susan E. Bates

### Correction: GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

Correction: GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
ABOUT THE COVER

RAF265 greatly reduces the activation of MEK1 in melanoma patient tumors. Photomicrograph showing immunohistochemical localization of a remaining low level of active phospho-MEK1 (green) in a melanoma patient tumor that was treated with RAF265 after being implanted into a nude mouse. Nuclei are stained with DAPI and appear blue. 20X magnification. For details, see the article by Su and colleagues on page 2184 of this issue.
Clinical Cancer Research

18 (8)


Updated version

Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/18/8

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.